We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

vrijdag 18 augustus 2017

Nature Reviews Nephrology - Table of Contents alert Volume 13 Issue 9

Nature Reviews Nephrology

 
TABLE OF CONTENTS
 
September 2017 Volume 13 Number 9
Nature Reviews Nephrology cover
2016 2-year Impact Factor 12.146 Journal Metrics 2-year Median 9
In this issue
Research Highlights
News and Views
Reviews
Correspondence

Also this month
 Featured article:
Diabetes mellitus: Cardiovascular and renal benefits of SGLT2 inhibition: insights from CANVAS
Volker Vallon & Scott C. Thomson


Subscribe
 
Facebook
 
RSS
 
Recommend to library
 
Twitter
 
RESEARCH HIGHLIGHTS
Top

Polycystic kidney disease: SMYD2 is a novel epigenetic regulator of cyst growth
Published online: 03 July 2017
p513 | doi:10.1038/nrneph.2017.99

PDF


Cell biology: Connexin connections in GN
Published online: 17 July 2017
p514 | doi:10.1038/nrneph.2017.106

PDF


Diabetic nephropathy: Restoring podocyte proteostasis in DN
Published online: 24 July 2017
p514 | doi:10.1038/nrneph.2017.111

PDF


Chronic kidney disease: Role of suPAR in APOL1-associated kidney disease
Published online: 03 July 2017
p514 | doi:10.1038/nrneph.2017.97

PDF


Infection: Impeding UPEC gut colonization
Published online: 17 July 2017
p515 | doi:10.1038/nrneph.2017.96

PDF


Nature Reviews Nephrology
JOBS of the week
Post Doctoral Fellow
University of Colorado Anschutz Medical Campus
Position for a Post-Doctoral Research Fellow in Functional Cancer Genomics and DNA Transposase Biology
Memorial Sloan Kettering Cancer Center (MSKCC)
Faculty Position in Innate Immunity Job
Mayo Clinic
More Science jobs from
Nature Reviews Nephrology
EVENT
The 5th International Conference on PreHypertension, Hypertension and CMS
22.02.18
Venice, Italy
More science events from
 
NEWS AND VIEWS
Top
Diabetes mellitus: Cardiovascular and renal benefits of SGLT2 inhibition: insights from CANVAS
Volker Vallon & Scott C. Thomson
Published online: 07 August 2017
p517 | doi:10.1038/nrneph.2017.113
Inhibitors of renal sodium/glucose cotransporter 2 (SGLT2) are new anti-hyperglycaemic drugs that reduce proximal tubular glucose and sodium reabsorption. The Canagliflozin Cardiovascular Assessment Study (CANVAS) Program is the second major trial to demonstrate beneficial effects of SGLT2 inhibitors on the kidney and cardiovascular system in patients with type 2 diabetes mellitus.
Full Text | PDF

Polycystic kidney disease: DZIP1L defines a new functional zip code for autosomal recessive PKD
Erum A. Hartung & Lisa M. Guay-Woodford
Published online: 24 July 2017
p519 | doi:10.1038/nrneph.2017.102
New findings demonstrate a link between mutations in DZIP1L and an autosomal recessive polycystic kidney disease (ARPKD)-like phenotype. Rather than focus on DZIP1L as a second genetic locus for ARPKD, we suggest these data identify the ciliary transition zone as a functional domain central to the pathogenesis of ARPKD.
Full Text | PDF

Diabetes mellitus: Complex interplay between metformin, AKI and lactic acidosis
Connie M. Rhee & Kamyar Kalantar-Zadeh
Published online: 24 July 2017
p521 | doi:10.1038/nrneph.2017.105
Debate exists regarding the safety of metformin and the risk of metformin-associated lactic acidosis, particularly in the setting of kidney dysfunction. Data from two studies examining the interplay between metformin, acute kidney injury, and complications including lactic acidosis suggest that metformin should be used conservatively in patients with kidney dysfunction.
Full Text | PDF

Renal injury: Early apoptotic extracellular vesicles in injury and repair
Benedetta Bussolati & Giovanni Camussi
Published online: 18 August 2017
p523 | doi:10.1038/nrneph.2017.117
During injury, mitogenic signals from apoptotic cells may compensate for cell loss by promoting organ homeostasis and regeneration. A distinct type of early apoptotic extracellular vesicle with specific mitogenic activity has been identified. The detection of these vesicles in damaged mouse glomeruli highlights their possible role in response to renal injury.
Full Text | PDF

 
REVIEWS
Top
Uromodulin: from physiology to rare and complex kidney disorders
Olivier Devuyst, Eric Olinger & Luca Rampoldi
Published online: 07 August 2017
p525 | doi:10.1038/nrneph.2017.101
Uromodulin is the most abundant urinary protein. Here, the authors discuss the physiological roles of uromodulin, the mechanisms by which mutations in the UMOD gene, which encodes uromodulin, cause autosomal dominant tubulointerstitial kidney disease and the association of common UMOD variants with complex disorders in the general population.
Abstract | Full Text | PDF

Extracellular vesicles in renal disease
Diana Karpman, Anne-lie Ståhl & Ida Arvidsson

Published online: 24 July 2017
p545 | doi:10.1038/nrneph.2017.98
Extracellular vesicles, exosomes and microvesicles are host cell-derived packages of information that are involved in cell-cell communication. This Review discusses how the release and uptake of these vesicles has important physiological functions in renal processes and can contribute to the development of kidney diseases, and how extracellular vesicles might be targeted and used for the treatment of patients with renal diseases.
Abstract | Full Text | PDF

Treatment of membranous nephropathy: time for a paradigm shift
Piero Ruggenenti, Fernando C. Fervenza & Giuseppe Remuzzi
Published online: 03 July 2017
p563 | doi:10.1038/nrneph.2017.92
Membranous nephropathy is an immune-mediated disease and is the leading cause of nephrotic syndrome in adults. Here, the authors discuss the role of B cell-depleting regimens in the treatment of this disease and the potential use of rescue therapy with agents that target plasma cells, which might prevent antigen-antibody interactions and immune complex-mediated complement activation.
Abstract | Full Text | PDF

Mechanisms and consequences of carbamoylation
Sigurd Delanghe, Joris R. Delanghe, Reinhart Speeckaert, Wim Van Biesen & Marijn M. Speeckaert
Published online: 31 July 2017
p580 | doi:10.1038/nrneph.2017.103
Patients with chronic kidney disease have elevated levels of carbamoylated proteins. Here the authors review the mechanisms of carbamoylation, the effects of this post-translational modification on renal function and strategies to reduce the carbamoylation load.
Abstract | Full Text | PDF

 
CORRESPONDENCE
Top
Experimental concerns regarding suPAR-related proteinuria
Laurent Mesnard, Yosu Luque & Eric Rondeau
Published online: 31 July 2017
p593 | doi:10.1038/nrneph.2017.108

Full Text | PDF
 
REPLY
Top
SuPAR and FSGS: is the jury still out?
Lorenzo Gallon & Susan E. Quaggin
Published online: 31 July 2017
p593 | doi:10.1038/nrneph.2017.109

Full Text | PDF
 
CORRESPONDENCE
Top
Intravenous hydroxocobalamin and crystal nephropathy
Matthieu Legrand & Vincent Mallet
Published online: 31 July 2017
p593 | doi:10.1038/nrneph.2017.110

Full Text | PDF
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events
Nature Reviews Nephrology was previously published as Nature Clinical Practice Nephrology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount
(You will need to log in to be recognised as a nature.com registrant).

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our feedback department

Springer Nature | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2017 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature